The sepsis therapeutics market size has grown strongly in recent years. It will grow from $4.39 billion in 2025 to $4.82 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to limited availability of advanced sepsis therapeutics, high prevalence of hospital-acquired infections, reliance on conventional antibiotics, growing awareness of sepsis management, inadequate critical care infrastructure.
The sepsis therapeutics market size is expected to see strong growth in the next few years. It will grow to $6.92 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to development of novel antibiotic classes and biologics, increasing investment in sepsis research, expansion of hospital critical care units, adoption of advanced patient monitoring technologies, integration of telemedicine and digital health solutions. Major trends in the forecast period include rising adoption of injectable sepsis therapeutics, expansion of hospital and critical care facilities, development of broad-spectrum antibiotics, increasing focus on patient monitoring and early diagnosis, growth in telemedicine and remote healthcare solutions.
The growing prevalence of infectious diseases is expected to drive the sepsis therapeutics market forward. Infectious diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, are on the rise, primarily due to climate change. Changing temperatures and ecosystems are expanding the habitats of disease-carrying vectors such as mosquitoes, leading to the spread of illnesses such as malaria and dengue fever. Sepsis therapeutics address these infectious diseases by targeting the infection itself, reducing inflammation, and supporting organ function to prevent life-threatening complications. According to the National Library of Medicine, in January 2023, infectious diseases are responsible for over 52 million deaths annually, with nearly half of the global population at risk. Each year, approximately 14 million children under five die, and 70% of these deaths are linked to preventable diseases that could be avoided through vaccination. Thus, the increasing prevalence of infectious diseases is a key factor driving the growth of the sepsis therapeutics market.
Companies in the sepsis diagnostics market are focused on developing innovative diagnostic technologies to improve sepsis detection and management. Advances in rapid molecular tests, which can detect pathogens quickly and accurately, are crucial for early diagnosis, better patient outcomes, and reduced mortality rates caused by delayed detection. These rapid molecular tests use advanced techniques such as PCR or isothermal amplification to identify pathogens by detecting their genetic material. For example, in November 2023, Inflammatix Inc., a US-based biotechnology company, announced the completion of its TriVerity Acute Infection and Sepsis Test System. This system includes the Myrna Instrument and the TriVerity Cartridge, designed for emergency department use to assess the likelihood of bacterial or viral infections and the risk of acute decompensation in patients with suspected infections and sepsis.
In January 2025, Partner Therapeutics, Inc. (PTx), a US-based biotechnology company specializing in sepsis therapeutics, partnered with the Biomedical Advanced Research and Development Authority (BARDA) to fund a Phase 2 study on the safety and optimal dosing of LEUKINE (sargramostim, rhu GM-CSF) in sepsis patients. This collaboration aims to enhance sepsis treatment by developing tools to measure immune status, enabling more targeted immunomodulatory therapies. BARDA, a US government department dedicated to biomedical advanced research, is supporting this initiative.
Major companies operating in the sepsis therapeutics market are Pfizer Inc, AstraZeneca plc, GSK plc, Eli Lilly and Company, Viatris Inc, Astellas Pharma Inc, La Jolla Pharmaceutical Company, Aridis Pharmaceuticals Inc, Partner Therapeutics Inc, InflaRx GmbH, Adrenomed AG, Sepsia Therapeutics, Endpoint Health, Prenosis Inc, Spectral Medical Inc, Modus Therapeutics, Cytovale Inc, T2 Biosystems Inc, AbbVie Inc, Merck and Co Inc.
North America was the largest region in the sepsis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sepsis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sepsis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the sepsis therapeutics market by increasing costs of imported active pharmaceutical ingredients (APIs) and specialized drug formulations. Segments such as injectable therapeutics and novel biologics are particularly impacted, with Asia-Pacific regions including India and China facing higher import duties. This has led to increased treatment costs and supply chain adjustments. On the positive side, tariffs have encouraged local drug manufacturing, promoted investment in domestic pharmaceutical capabilities, and fostered innovation in cost-effective sepsis therapies.
The sepsis therapeutics market research report is one of a series of new reports that provides sepsis therapeutics market statistics, including sepsis therapeutics industry global market size, regional shares, competitors with a sepsis therapeutics market share, detailed sepsis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the sepsis therapeutics industry. This sepsis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Sepsis therapeutics refer to the medical treatments and medications specifically aimed at managing sepsis, a life-threatening condition triggered by the body's extreme response to infection. The primary objective of these treatments is to control the infection, sustain vital functions, manage inflammation, and avert organ failure, thereby enhancing survival rates and aiding in patient recovery.
The key drug categories used in sepsis treatment include cephalosporins, aminoglycosides, glycopeptides, among others. Cephalosporins, a class of broad-spectrum antibiotics, are frequently prescribed for sepsis and other serious bacterial infections. These drugs can be administered through various methods, such as orally, via injection, or topically. They are distributed through different channels, including hospital pharmacies, retail pharmacies, and online platforms. These medications are primarily used in settings such as hospitals, clinics, and other healthcare environments.
The sepsis therapeutics market consists of revenues earned by entities providing services such as pharmaceutical interventions, supportive therapies, and diagnostic solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The sepsis therapeutics market also includes sales of antibiotics, intravenous fluids, vasopressors, and advanced therapies aimed at controlling infection, stabilizing patients, and preventing organ failure. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The sepsis therapeutics market size is expected to see strong growth in the next few years. It will grow to $6.92 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to development of novel antibiotic classes and biologics, increasing investment in sepsis research, expansion of hospital critical care units, adoption of advanced patient monitoring technologies, integration of telemedicine and digital health solutions. Major trends in the forecast period include rising adoption of injectable sepsis therapeutics, expansion of hospital and critical care facilities, development of broad-spectrum antibiotics, increasing focus on patient monitoring and early diagnosis, growth in telemedicine and remote healthcare solutions.
The growing prevalence of infectious diseases is expected to drive the sepsis therapeutics market forward. Infectious diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, are on the rise, primarily due to climate change. Changing temperatures and ecosystems are expanding the habitats of disease-carrying vectors such as mosquitoes, leading to the spread of illnesses such as malaria and dengue fever. Sepsis therapeutics address these infectious diseases by targeting the infection itself, reducing inflammation, and supporting organ function to prevent life-threatening complications. According to the National Library of Medicine, in January 2023, infectious diseases are responsible for over 52 million deaths annually, with nearly half of the global population at risk. Each year, approximately 14 million children under five die, and 70% of these deaths are linked to preventable diseases that could be avoided through vaccination. Thus, the increasing prevalence of infectious diseases is a key factor driving the growth of the sepsis therapeutics market.
Companies in the sepsis diagnostics market are focused on developing innovative diagnostic technologies to improve sepsis detection and management. Advances in rapid molecular tests, which can detect pathogens quickly and accurately, are crucial for early diagnosis, better patient outcomes, and reduced mortality rates caused by delayed detection. These rapid molecular tests use advanced techniques such as PCR or isothermal amplification to identify pathogens by detecting their genetic material. For example, in November 2023, Inflammatix Inc., a US-based biotechnology company, announced the completion of its TriVerity Acute Infection and Sepsis Test System. This system includes the Myrna Instrument and the TriVerity Cartridge, designed for emergency department use to assess the likelihood of bacterial or viral infections and the risk of acute decompensation in patients with suspected infections and sepsis.
In January 2025, Partner Therapeutics, Inc. (PTx), a US-based biotechnology company specializing in sepsis therapeutics, partnered with the Biomedical Advanced Research and Development Authority (BARDA) to fund a Phase 2 study on the safety and optimal dosing of LEUKINE (sargramostim, rhu GM-CSF) in sepsis patients. This collaboration aims to enhance sepsis treatment by developing tools to measure immune status, enabling more targeted immunomodulatory therapies. BARDA, a US government department dedicated to biomedical advanced research, is supporting this initiative.
Major companies operating in the sepsis therapeutics market are Pfizer Inc, AstraZeneca plc, GSK plc, Eli Lilly and Company, Viatris Inc, Astellas Pharma Inc, La Jolla Pharmaceutical Company, Aridis Pharmaceuticals Inc, Partner Therapeutics Inc, InflaRx GmbH, Adrenomed AG, Sepsia Therapeutics, Endpoint Health, Prenosis Inc, Spectral Medical Inc, Modus Therapeutics, Cytovale Inc, T2 Biosystems Inc, AbbVie Inc, Merck and Co Inc.
North America was the largest region in the sepsis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sepsis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sepsis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the sepsis therapeutics market by increasing costs of imported active pharmaceutical ingredients (APIs) and specialized drug formulations. Segments such as injectable therapeutics and novel biologics are particularly impacted, with Asia-Pacific regions including India and China facing higher import duties. This has led to increased treatment costs and supply chain adjustments. On the positive side, tariffs have encouraged local drug manufacturing, promoted investment in domestic pharmaceutical capabilities, and fostered innovation in cost-effective sepsis therapies.
The sepsis therapeutics market research report is one of a series of new reports that provides sepsis therapeutics market statistics, including sepsis therapeutics industry global market size, regional shares, competitors with a sepsis therapeutics market share, detailed sepsis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the sepsis therapeutics industry. This sepsis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Sepsis therapeutics refer to the medical treatments and medications specifically aimed at managing sepsis, a life-threatening condition triggered by the body's extreme response to infection. The primary objective of these treatments is to control the infection, sustain vital functions, manage inflammation, and avert organ failure, thereby enhancing survival rates and aiding in patient recovery.
The key drug categories used in sepsis treatment include cephalosporins, aminoglycosides, glycopeptides, among others. Cephalosporins, a class of broad-spectrum antibiotics, are frequently prescribed for sepsis and other serious bacterial infections. These drugs can be administered through various methods, such as orally, via injection, or topically. They are distributed through different channels, including hospital pharmacies, retail pharmacies, and online platforms. These medications are primarily used in settings such as hospitals, clinics, and other healthcare environments.
The sepsis therapeutics market consists of revenues earned by entities providing services such as pharmaceutical interventions, supportive therapies, and diagnostic solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The sepsis therapeutics market also includes sales of antibiotics, intravenous fluids, vasopressors, and advanced therapies aimed at controlling infection, stabilizing patients, and preventing organ failure. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Sepsis Therapeutics Market Characteristics
3. Sepsis Therapeutics Market Supply Chain Analysis
4. Global Sepsis Therapeutics Market Trends and Strategies
5. Sepsis Therapeutics Market Analysis of End Use Industries
7. Global Sepsis Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Sepsis Therapeutics Total Addressable Market (TAM) Analysis for the Market
9. Sepsis Therapeutics Market Segmentation
10. Sepsis Therapeutics Market Regional and Country Analysis
11. Asia-Pacific Sepsis Therapeutics Market
12. China Sepsis Therapeutics Market
13. India Sepsis Therapeutics Market
14. Japan Sepsis Therapeutics Market
15. Australia Sepsis Therapeutics Market
16. Indonesia Sepsis Therapeutics Market
17. South Korea Sepsis Therapeutics Market
18. Taiwan Sepsis Therapeutics Market
19. South East Asia Sepsis Therapeutics Market
20. Western Europe Sepsis Therapeutics Market
21. UK Sepsis Therapeutics Market
22. Germany Sepsis Therapeutics Market
23. France Sepsis Therapeutics Market
24. Italy Sepsis Therapeutics Market
25. Spain Sepsis Therapeutics Market
26. Eastern Europe Sepsis Therapeutics Market
27. Russia Sepsis Therapeutics Market
28. North America Sepsis Therapeutics Market
29. USA Sepsis Therapeutics Market
30. Canada Sepsis Therapeutics Market
31. South America Sepsis Therapeutics Market
32. Brazil Sepsis Therapeutics Market
33. Middle East Sepsis Therapeutics Market
34. Africa Sepsis Therapeutics Market
36. Sepsis Therapeutics Market Competitive Landscape and Company Profiles
37. Sepsis Therapeutics Market Other Major and Innovative Companies
40. Sepsis Therapeutics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Sepsis Therapeutics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses sepsis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for sepsis therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sepsis therapeutics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Class: Cephalosporin; Aminoglycosides; Glycopeptide; Other Drug Classes2) By Route Of Administration: Oral; Injectable
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By Application: Hospitals; Clinics; Other Applications
Subsegments:
1) By Cephalosporin: First-Generation Cephalosporins; Second-Generation Cephalosporins; Third-Generation Cephalosporins; Fourth-Generation Cephalosporins; Fifth-Generation Cephalosporins2) By Aminoglycosides: Gentamicin; Amikacin; Tobramycin; Streptomycin; Other Aminoglycosides
3) By Glycopeptide: Vancomycin; Teicoplanin; Dalbavancin; Oritavancin; Other Glycopeptides
4) By Other Drug Classes: Carbapenems; Beta-Lactamase Inhibitors; Fluoroquinolones; Macrolides; Polymyxins
Companies Mentioned: Pfizer Inc; AstraZeneca plc; GSK plc; Eli Lilly and Company; Viatris Inc; Astellas Pharma Inc; La Jolla Pharmaceutical Company; Aridis Pharmaceuticals Inc; Partner Therapeutics Inc; InflaRx GmbH; Adrenomed AG; Sepsia Therapeutics; Endpoint Health; Prenosis Inc; Spectral Medical Inc; Modus Therapeutics; Cytovale Inc; T2 Biosystems Inc; AbbVie Inc; Merck and Co Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Sepsis Therapeutics market report include:- Pfizer Inc
- AstraZeneca plc
- GSK plc
- Eli Lilly and Company
- Viatris Inc
- Astellas Pharma Inc
- La Jolla Pharmaceutical Company
- Aridis Pharmaceuticals Inc
- Partner Therapeutics Inc
- InflaRx GmbH
- Adrenomed AG
- Sepsia Therapeutics
- Endpoint Health
- Prenosis Inc
- Spectral Medical Inc
- Modus Therapeutics
- Cytovale Inc
- T2 Biosystems Inc
- AbbVie Inc
- Merck and Co Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.82 Billion |
| Forecasted Market Value ( USD | $ 6.92 Billion |
| Compound Annual Growth Rate | 9.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
